期刊文献+

Smoking and Serum Lipid Profiles in Schizophrenia 被引量:2

Smoking and Serum Lipid Profiles in Schizophrenia
原文传递
导出
摘要 Schizophrenia is associated with a high preva- lence of cigarette-smoking and abnormal lipid profiles. The purpose of this study was to determine whether the profiles differ between schizophrenic smokers and non-smokers and whether the lipid profiles are related to psychopathological symptoms. Serum lipid profiles were measured in 130 male inpatients with DSM-IV-defined schizophrenia: 104 smokers and 26 non-smokers. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Our results showed that positive PANSS symp- toms were fewer in smokers than in non-smokers, while the negative symptoms were fewer in those who smoked more cigarettes. Total protein and globulin levels were significantly lower in the smokers than in the non-smokers. However, there was no significant difference in total cholesterol, triglycerides, high-density lipoprotein choles terol (HDL-c), low-density lipoprotein cholesterol, apolipoprotein A1, or apolipoprotein B between the smokers and non-smokers. However, the PANSS positive subscale had a significant negative correlation with the HDL-c levels (a protective factor) in the smokers but not in the non-smokers. Our findings suggest that schizophrenic patients who smoke have fewer psychotic symptoms, but contrary to expectation, smoking does not alter lipid profile levels. Schizophrenia is associated with a high preva- lence of cigarette-smoking and abnormal lipid profiles. The purpose of this study was to determine whether the profiles differ between schizophrenic smokers and non-smokers and whether the lipid profiles are related to psychopathological symptoms. Serum lipid profiles were measured in 130 male inpatients with DSM-IV-defined schizophrenia: 104 smokers and 26 non-smokers. Symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS). Our results showed that positive PANSS symp- toms were fewer in smokers than in non-smokers, while the negative symptoms were fewer in those who smoked more cigarettes. Total protein and globulin levels were significantly lower in the smokers than in the non-smokers. However, there was no significant difference in total cholesterol, triglycerides, high-density lipoprotein choles terol (HDL-c), low-density lipoprotein cholesterol, apolipoprotein A1, or apolipoprotein B between the smokers and non-smokers. However, the PANSS positive subscale had a significant negative correlation with the HDL-c levels (a protective factor) in the smokers but not in the non-smokers. Our findings suggest that schizophrenic patients who smoke have fewer psychotic symptoms, but contrary to expectation, smoking does not alter lipid profile levels.
出处 《Neuroscience Bulletin》 SCIE CAS CSCD 2016年第4期383-388,共6页 神经科学通报(英文版)
基金 supported by the National Natural Science Foundation of China(81371477) the Beijing Municipal Natural Science Foundation(7132063 and 7072035) a National Alliance for Research on Schizophrenia and Depression Independent Investigator Grant(20314)
关键词 SCHIZOPHRENIA NICOTINE Cigarettesmoking Lipid profiles SYMPTOMS Schizophrenia Nicotine Cigarettesmoking Lipid profiles Symptoms
  • 相关文献

参考文献41

  • 1de Leon J, Diaz F. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr Res 2005, 76: 135-157.
  • 2Sagud M, Mihaljevic-Peles A, Muck-SeIer D, Pivac N, VuksanCusa B, Brataljenovic T, et al. Smoking and schizophrenia. Psychiatr Danub 2009, 21: 371-375.
  • 3Dickerson F, Stallings CR, Origoni AB, Vaughan C, Khushalani S, Schroeder J, et al. Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999-2011. Psychiatr Serv 2013, 64: 44-50.
  • 4Zhang XY, Liang J, Chen da C, Xiu MH, He J, Cheng W, et al. Cigarette smoking in male patients with chronic schizophrenia in a Chinese population: prevalence and relationship to clinical phenotypes. PLoS One 2012, 7(2): e30937.
  • 5Williams JM, Ziedonis DM, Abanyie F, Steinberg ML, Foulds J, Benowitz NL. Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect. Schizophr Res 2005, 79(2-3): 323-335.
  • 6Kumari V, & Postma P. Nicotine use in schizophrenia: the self medication hypotheses. Neurosci Biobehav Rev 2005, 29: 1021-1034.
  • 7Winterer G. Why do patients with schizophrenia smoke? CUIT Opin Psychiatry 2010, 23(2):112-119.
  • 8Featherstone RE, Siegel SJ. The Role of Nicotine in Schizophrenia. Int Rev Neurobiol 2015, 124: 23-78.
  • 9Boehm G, Racoosin JA, Laughren TP, Katz R. Consensus development conference on antipsychotic drugs and obesity and diabetes: response to consensus statement. Diabetes Care 2004, 27: 2088-2089.
  • 10Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, et al. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004, 65(Suppl 7): 4-18.

同被引文献4

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部